Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021383 | 0.85 | ADORA1 (0.59) | ADORA1ADORA2AGRM4 | |
| SCHEMBL8076723 | 0.85 | ACHE (0.42) | KMT2AKDRMEN1MAPTBLM | |
| SCHEMBL10936938 | 0.83 | ADORA1 (0.58) | KMT2AADORA1ADORA2ARPS6KA3MAP3K14 | |
| SCHEMBL21121012 | 0.82 | KMT2A (0.43) | KMT2AADORA1ADORA2ARPS6KA3MAP3K14 | |
| SCHEMBL31339965 | 0.82 | KMT2A (0.71) | KMT2AADORA1ADORA2AMEN1MAPT | |
| SCHEMBL28406688 | 0.82 | DHFR (0.56) | KMT2AADORA1ADORA2ARPS6KA3MAP3K14 | |
| SCHEMBL16585820 | 0.81 | PDK1 (0.40) | KMT2AMEN1MAPTKDM4ENPC1 | |
| SCHEMBL21121008 | 0.81 | ADORA1 (0.42) | KMT2AADORA1ADORA2ARPS6KA3MAP3K14 | |
| SCHEMBL3397294 | 0.81 | HRH3 (0.51) | KMT2AADORA1ADORA2ARPS6KA3 | |
| SCHEMBL4541570 | 0.80 | IKBKB (0.48) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111065635-A | Novel pyrimidine derivatives as MTH1 inhibitors | 无锡安万生物科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| WO-2019134082-A1 | NOVEL PYRIMIDINE DERIVATIVES AS MTH1 INHIBITORS | WUXI ADVANT BIOTECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | WO | claimed |
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | JILIN UNIVERSITY (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4725485-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | Jilin University (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-119285557-A | CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof | 吉林大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-111065635-B | Novel pyrimidine derivatives as MTH1 inhibitors | 无锡安万生物科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-111065635-A | Novel pyrimidine derivatives as MTH1 inhibitors | 无锡安万生物科技有限公司 | 2020-04-24 | — | — | CN | disclosed |
| WO-2019134082-A1 | NOVEL PYRIMIDINE DERIVATIVES AS MTH1 INHIBITORS | WUXI ADVANT BIOTECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019134082-A1 | NOVEL PYRIMIDINE DERIVATIVES AS MTH1 INHIBITORS | WUXI ADVANT BIOTECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | GZMB, CD74, GSDMD | KMT2A 1740/4885ADORA1 1820/4885ADORA2A 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.